NLRP3 and major depressive disorder: A better understanding of the multifaceted mechanisms of the actions of these atypical drugs on NLRP3 inflammasome signaling can be postulated to contribute to improvements in the efficiency of the pharmacotherapy of depression, particularly in that associated with microglia immunoactivation.